1 – 10 of 14
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2020
- [11C]PIB amyloid quantification : effect of reference region selection
- Amyloid-β PET and CSF in an autopsy-confirmed cohort
- Test–retest repeatability of [18F]Flortaucipir PET in Alzheimer’s disease and cognitively normal individuals
- Why Is Amyloid-β PET Requested After Performing CSF Biomarkers?
- Tau pathology and relative cerebral blood flow are independently associated with cognition in Alzheimer’s disease
- Regional [18F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer’s disease
- Combination of plasma amyloid beta(1-42/1-40)and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology
- 2019
- Discordant amyloid-β PET and CSF biomarkers and its clinical consequences
- Associations between quantitative [18F]flortaucipir tau PET and atrophy across the Alzheimer's disease spectrum
- Amyloid-β load is related to worries, but not to severity of cognitive complaints in individuals with subjective cognitive decline : The science project